The Discounted Cash Flow (DCF) valuation of BridgeBio Pharma Inc (BBIO) is (73.30) USD. With the latest stock price at 28.98 USD, the upside of BridgeBio Pharma Inc based on DCF is -352.9%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.9% - 8.6% | 7.7% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (134.88) - (52.85) | (73.30) |
| Upside | -565.4% - -282.4% | -352.9% |